News und Analysen
4 Reasons to Buy Intuitive Surgical, Inc. Stock and Never Sell
Before starting, a confession is in order: Over the seven years that I've been a shareholder of Intuitive Surgical (NASDAQ: ISRG), there was a time that I actually sold some of the stock. My....
Allergan's Patent Loophole Could Be a Huge Gift for Pfizer
The tribe has spoken.On Friday, Allergan (NYSE: AGN) announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. Both parties should win from....
Slash Your Medicare Drug Costs With These 6 Tips
IMAGE SOURCE: GETTY IMAGES.If you're one of the millions of Americans with Medicare Part D or Medicare Advantage coverage, or if you're signing up for one of these plans for the first time, then....
Why a New Wave of Stock Splits Could Be on the Horizon
Throughout most of the stock market's history, stock splits played a vital role in helping companies control share prices. Recently, though, many companies have stopped doing stock splits even....
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis (NASDAQ: EXEL) was one of the top biotech stocks of 2016. It's also one of the best biotech stocks so far this year. However, Exelixis shares have pulled back in recent days, primarily....
2 Dividend Stocks You Can Buy and Hold Forever
If you'd like to park your money in stocks and monitor them as little as possible, you need to choose them extra carefully. There's no guarantee that even today's most successful companies won't....
Is a Med-Tech Marriage in Mazor Robotics' Future?
Medtronic's (NYSE: MDT) salespeople have been generating leads for Mazor Robotics' (NASDAQ: MZOR) robotic surgery system since last year, and recently, the two companies agreed to let Medtronic....
CAR-T Mania: Could Juno Therapeutics Get Acquired Next?
Gilead Sciences (NASDAQ: GILD) recently acquired Kite Pharma (NASDAQ: KITE), but that doesn't mean an acquisition of Juno Therapeutics (NASDAQ: JUNO) is off the table. Juno Therapeutics'....
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
Every biotech company goes into a clinical study with great hopes -- and often great fears, as well. There's no guarantee that all will go well. All the time and money poured into an experimental....
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Shares of Exelixis (NASDAQ: EXEL), a biotech company primarily focused on developing drugs to treat cancer, rallied more than $2 per share during the month of August, according to data from....
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three....
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial....
Why Clovis Oncology Fell 7.1% in August
Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed....
Why Illumina Rose 18.7% in August
Shares of Illumina (NASDAQ: ILMN), a leading manufacturer of genetic testing equipment, rose 18.7% in August, according to data from S&P Global Market Intelligence. Investors can thank solid....
Here's Why Spark Therapeutics Inc. Surged 23.5% in August
Shares of Spark Therapeutics Inc. (NASDAQ: ONCE), a clinical-stage biotech developing gene therapies, rose 23.5% in August, according to data from S&P Global Market Intelligence. The company....
Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, soared 40% in August, according to data from S&P Global Market Intelligence. A generous....
Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market....
Here's Why Novo Nordisk A/S Gained 12% in August
Shares of Danish pharma giant Novo Nordisk A/S (NYSE: NVO) rose 11.7% in August, according to data from S&P Global Market Intelligence. Investors were relieved to see that the sales stall the....
7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020
Image source: Getty Images.Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky -- nearly four-tenths of the way to the moon. That stack would total $1.4....
The Key Reason Incyte Corporation Added $850 Million in Market Cap in August
Shares of Incyte (NASDAQ: INCY), a large-cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases, tacked on more than $4 per share, or $850 million....
Why Juno Therapeutics Shares Vaulted 46% Higher in August
After Gilead Sciences (NASDAQ: GILD) scooped up competitor Kite Pharma (NASDAQ: KITE) for $11.9 billion and Novartis (NYSE: NVS) secured an approval from the Food and Drug Administration for....
Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
I bought my shares of Johnson & Johnson (NYSE: JNJ) and Gilead Sciences, Inc. (NASDAQ: GILD) long ago, when they were trading far lower than they are today. If I had to choose one to keep and....
Here's the Best Dividend Stock in Big Pharma
Dividends make a huge impact on your overall investing returns. They can also provide solid income during your retirement years. Historically, big pharma stocks have been a great place for....
Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market....
3 Biotech Stocks That Skyrocketed This Week
If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by....